Please assess the completion status of the following clinical trial:

Trial Title: Comparison of Three Anti-HIV Regimens to Prevent Nevirapine Resistance in Women Who Take Nevirapine During Pregnancy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria for Mothers:~* HIV-1 infected~* CD4 count 250 cells/mm3 or greater within 30 days of study entry~* The following laboratory values obtained within 30 days prior to study entry: absolute neutropil count \>= 750/mm3; hemoglobin \>= 8.0 g/dL; platelet count \>= 50,000/mm3; calculated creatinine clearance (Cockcroft-Gault formula) \> 60 mL/min; AST(SGOT) and ALT(SGPT) \< 5 x ULN; total bilirubin \< 1.5 X ULN.~* Pregnant with a viable fetus at 28 to 38 weeks gestation at study entry.~* Willing to give birth to baby in a hospital or clinic~* Written informed consent from parent or guardian, if applicable~Exclusion Criteria for Mothers:~* Any ART, including single-dose NVP, prior to study entry. Mothers who receive ZDV monotherapy prior to labor under the supervision of the site investigator are not excluded.~* Known allergy or sensitivity to study drugs or their formulations~* Current drug or alcohol abuse that may interfere with the study~* Serious illness requiring systemic treatment or hospitalization. Participants who complete therapy or are clinically stable on therapy for at least 14 days prior to study entry are not excluded.~* Hepatitis B surface antigen positive within 180 days prior to study entry~* Active tuberculosis infection requiring treatment~* Prior enrollment in this study~* Expect to use ART, except ZDV monotherapy, prior to onset of labor~* Expect to use ART other than study medications from delivery to 9 weeks postpartum

- Gender: FEMALE
- Minimum Age: 13 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 7-day 3TC/ZDV (Type: EXPERIMENTAL): SD NVP and 3TC/ZDV provided at onset of active labor, followed by 7 days of 3TC/ZDV.
- 21-day 3TC/ZDV (Type: EXPERIMENTAL): SD NVP and 3TC/ZDV provided at onset of active labor, followed by 21 days of 3TC/ZDV.
- 7-day FTC/TDF (Type: EXPERIMENTAL): SD NVP and FTC/TDF provided at onset of active labor, followed by 7 days of FTC/TDF.
- 21-day FTC/TDF (Type: EXPERIMENTAL): SD NVP and FTC/TDF provided at onset of active labor, followed by 21 days of FTC/TDF.
- 7-day LPV/r (Type: EXPERIMENTAL): SD NVP and LPV/r provided at onset of active labor, followed by 7 days of LPV/r.
- 21-day LPV/r (Type: EXPERIMENTAL): SD NVP and LPV/r provided at onset of active labor, followed by 7 days of LPV/r

Based on this trial design, predict the completion outcome and termination type (if applicable).